Authors
Latest:
NICE approves idebenone for treating LHONNICE approves idebenone for Leber hereditary optic neuropathy, offering hope for vision restoration and improved quality of life for patients.
Latest:
A realistic outlook on diabetes remission: GLP-1 therapies, diabetic retinopathy’s futureGLP-1 therapies could impact long-term outcomes in diabetic retinopathy.
Latest:
Subretinal drusenoid deposits: Marker for unrecognized cardiac diseaseNew research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need for ophthalmologists to screen patients effectively.
Latest:
Emerging insights into ocular immune-related diseases and treatment optionsIn this study, researchers examine immune mechanisms in ocular diseases like uveitis, AMD, DR, and GO, highlighting microglial roles, targeted therapies, and promising advances in immunotherapy.
Latest:
Faricimab improves vision for minority patients with diabetic macular edemaStudy reveals faricimab effectively treats diabetic macular edema in underrepresented minorities, showing significant visual acuity improvements and safety across diverse patient populations.
Latest:
AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal diseaseThe platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests.
Latest:
Retina World Congress: Global innovations transforming treatment strategiesInternational retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025.
Latest:
High-resolution multimodal imaging is key in dry AMD therapeutic development, future managementIn an attempt to halt the progression of dry AMD and geographic atrophy, the use of high-resolution optical coherence tomography becomes pivotal.
Latest:
Effectiveness Of Pegcetacoplan In Preserving Visual Function In Geographic AtrophyDr Charles Wykoff presents the results of a post hoc microperimetry analysis from the OAKS study demonstrating the effectiveness of pegcetacoplan in preserving visual function.
Latest:
Wet AMD therapeutics: Technologies raising the ceiling for functional visual outcomesNeovascular macular degeneration is multifactorial, which requires future agents to target multiple pathways.
Latest:
Where might AI be heading?A look at the current state of AI in diabetic eye disease and where the future may take us.
Latest:
AAO 2024: Bonnie An Henderson, MD, explores future of medical education in Kelman LectureHenderson’s presentation touches on the shift in medical education from traditional learning to AI and robotics.
Latest:
Clinical Implications of Port Delivery System in Retinal DiseasesClosing out his discussion on the port delivery system in retinal diseases, Chirag Jhaveri, MD, considers how this approach has impacted the treatment landscape.
Latest:
How remote retinal imaging raises the bar across service, research and educationBaljean Dhillon, FRCPS, FRCS, FRCOphth, FRCPE, advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium.
Latest:
Vitrectomy: Is higher speed always better?Physicians should consider hydrodynamic cavitation when performing this procedure.
Latest:
Poll: Most anticipated emerging therapies in neovascular AMD and DMEA panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?
Latest:
Pearls for maintaining quality, safety in retina clinics amid a pandemicTo maintain treatment quality and patient and staff safety in the SARS-CoV-2 era, it is important to minimize clinic visits and maximize the use of imaging modalities. In addition, extending treatment intervals with longer-acting agents is key to maximizing safety and patients’ vision outcomes.
Latest:
Considerations for Incorporating GA Therapies Into Clinical PracticePanelists discuss how they manage patients requiring both wet age-related macular degeneration (AMD) and geographic atrophy (GA) treatments by administering injections on separate days rather than on the same day to avoid workflow disruption, address the increased intraocular pressure from the larger 100-µL complement inhibitor dose by allowing patients time to acclimate in the chair with only a small percentage requiring pressure-relieving taps, and acknowledge that although this dual-therapy population represents a minority of their patients undergoing complement modulation, these experienced injection recipients are typically very accepting of additional treatments.
Latest:
Setting a New Standard in Automated Tracked PerimetryInnovative new features build on the benefits of the iCare COMPASS Automated Perimeter
Latest:
OSN New York Retina 2024: Understanding how next-generation anti-VEGFs perform in real-world settings compared to trialsFerhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into their performance and safety beyond clinical trials.
Latest:
A case of a 79-year-old pseudophakic patient with AMD and rapidly progressing GAThe final case is presented by Dr Adam, showcasing a 79-year old patient with multiple diagnoses and rapid progression of geographic atrophy.
Latest:
CTS 2025: Christine Kay, MD, on OPGx-LCA5 clinical results translated into real-life changesPhase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.
Latest:
Ophthalmologist shares his story on Holocaust Remembrance DayJohn H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.
Latest:
Searching for durable therapies for diabetic macular edema amid the pandemicPatients’ reluctance to visit a clinic during the COVID-19 pandemic is pushing retina specialists to optimize therapy.
Latest:
First FDA-approved MacTel treatment performedNeurotech Pharmaceuticals performs the first ENCELTO procedure.
Latest:
Optimizing Care For Patients With Retinal DisordersKey takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
